A Clinician's Guide to PTSD Biomarkers and Their Potential Future Use
- PMID: 31975909
- PMCID: PMC6526852
- DOI: 10.1176/appi.focus.20170045
A Clinician's Guide to PTSD Biomarkers and Their Potential Future Use
Abstract
No clinically validated biomarkers have yet been found to assist in the diagnosis and treatment of posttraumatic stress disorder (PTSD). Innovation in clinical trial design, however, has led to the study of biomarkers as part of testing new medications and psychotherapies. There may soon be viable biomarkers to assist in diagnosis of PTSD and prediction of illness trajectory, severity, and functional outcomes; subtyping; and treatment selection. Processes for the identification and validation of biomarker findings are complex, involving several stages of clinical testing before use. The authors provide an overview of issues regarding the clinical use of PTSD biomarkers and examine a set of genetic, epigenetic, and other blood-based markers along with physiological markers currently proposed as candidate tests for PTSD. Studies that have identified candidate biomarkers with relevance to treatment selection in PTSD are discussed as a promising area of research that may lead to changes in clinical practice.
Keywords: Posttraumatic stress disorder; biological targets; biomarkers; precision medicine; trauma.
Conflict of interest statement
The authors report no financial relationships with commercial interests.
References
-
- Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Association, 2013
-
- Galatzer-Levy IR, Bryant RA. 636,120 ways to have posttraumatic stress disorder. Perspect Psychol Sci 2013; 8:651-662. - PubMed
-
- Ressler KJ, Schoomaker EB: Commentary on “The Army study to assess risk and resilience in servicemembers (Army STARRS)”: Army STARRS: a Framingham-like study of psychological health risk factors in soldiers. Psychiatry 2014; 77:120–129 - PubMed
Publication types
LinkOut - more resources
Full Text Sources